Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Traws Pharma Inc TRAW

Healthcare
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a... see more

Recent & Breaking News (NDAQ:TRAW)

Onconova Therapeutics, Inc. to Present Corporate Overview at Biotech Showcase 2017

GlobeNewswire January 5, 2017

Onconova and Cellworks Announce Presentation of Rigosertib Predictive Signature for Clinical Response in Myelodysplastic Syndromes (MDS) at 2016 ASH Annual Meeting

GlobeNewswire December 6, 2016

Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at 2016 ASH Annual Meeting

GlobeNewswire December 5, 2016

Onconova Therapeutics, Inc. Reports Recent Business Highlights and Third Quarter 2016 Financial Results

GlobeNewswire November 14, 2016

Onconova Announces Presentations Related to Rigosertib Clinical Studies in Myelodysplastic Syndromes at the 2016 ASH Annual Meeting

GlobeNewswire November 4, 2016

Onconova Therapeutics, Inc. to Present Corporate Update at 2016 BIO Investor Forum

GlobeNewswire October 13, 2016

Onconova to Host Key Opinion Leader Luncheon on Novel Approaches to Targeting the RAS Pathway in Oncology on Monday, October 17, in New York City

GlobeNewswire October 10, 2016

TechStockInsider.com: The Week Many Have Been Waiting For

PR Newswire September 26, 2016

Onconova Announces Successful End-of-Phase 2 Meeting with FDA for Oral Rigosertib and Azacitidine Combination

GlobeNewswire September 26, 2016

Onconova Therapeutics, Inc. to Present Corporate Updates at Upcoming Investor Conferences

GlobeNewswire September 7, 2016

Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2016 Financial Results

GlobeNewswire August 15, 2016

Onconova Therapeutics, Inc. Announces Timing for Second Quarter 2016 Financial Results

GlobeNewswire August 11, 2016

Onconova Closes Oversubscribed Rights Offering with Gross Proceeds of $17.4 Million

GlobeNewswire August 1, 2016

Onconova Announces Expiration of Oversubscribed Rights Offering

GlobeNewswire July 27, 2016

Onconova Adjusts Pricing of Rights Offering

GlobeNewswire July 22, 2016

Onconova Announces Enrollment of First Patient in Japan by SymBio

GlobeNewswire July 19, 2016

Onconova Announces Commencement of Subscription Period for Previously Announced Rights Offering

GlobeNewswire July 8, 2016

Onconova Reminds Shareholders That Rights Offering Ownership Day is Friday, July 1, 2016

GlobeNewswire July 1, 2016

Onconova Announces Price Range and Change of Key Dates for Rights Offering

GlobeNewswire June 29, 2016

Onconova Informs Stockholders of Key Dates Related to Announced Rights Offering

GlobeNewswire June 20, 2016